Analysts Say This Small-Cap Biopharmaceutical Stock Is A Buy
The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from current levels.
Why These 2 Biotech Stocks Could Be Must-Owns This May
After a massive rally last year, biotech stocks have underperformed since February of this year. The author of today’s article, however, believes that the selloff… Read More »Why These 2 Biotech Stocks Could Be Must-Owns This May
Promising Drug Candidates And New Approaches To Unmet Medical Needs Give These 2 Biotech Stocks Over 50% Upside Potential
“Investors in biotech stocks need to find targets with positive catalysts on the near- to mid-term horizon, including promising drug candidates and/or novel approaches to unmet medical needs.”
4 Lesser-Known Biotech Stocks To Get To Know
“Keep an open mind and remain objective as you read about lesser-known biotech stocks. You just might add a couple of big winners to your portfolio.”
4 Biotech Penny Stocks To Watch Heading Into May
Which biotech penny stocks are worth watching heading into the month of May?
New Stocks To Watch In Biotech, Tech & More
Companies involved in life sciences (including for COVID-19), home healthcare and cell therapies are among the six new biotech stocks to watch.
How To Play This Biotech Stock Headed For A Breakout (Or Breakdown)
A rectangle pattern has formed for the biotech stock featured in today’s article, and the author advises that “When this pattern is broken, a breakout or breakdown is expected.”
3 Upcoming Biotech Catalysts To Watch
“If you only have enough time to keep up with a handful of biotech catalysts that are on the way soon, these three are well worth your attention.”
Do These 2 Disruptive Small-Cap Biotech Stocks Have The Potential To Be Millionaire Makers?
Regarding the two stocks he highlights, the author of today’s article declares “these two small-caps are both first movers in healthcare sectors that are ripe for disruption, with massive opportunities over the next decade.”
This Oncology Company’s “Platform In A Pill” Cancer Treatment Could Be A Massive Opportunity
RAS mutations are the initiating genetic events in many cancers – and have proven to be extremely difficult to target. With its lead compound, however, the oncology company featured in today’s article is “looking to become the backbone of treatment for RAS-driven cancers.